These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

259 related articles for article (PubMed ID: 23670192)

  • 1. An essential role of antibodies in the control of Chikungunya virus infection.
    Lum FM; Teo TH; Lee WW; Kam YW; Rénia L; Ng LF
    J Immunol; 2013 Jun; 190(12):6295-302. PubMed ID: 23670192
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Early neutralizing IgG response to Chikungunya virus in infected patients targets a dominant linear epitope on the E2 glycoprotein.
    Kam YW; Lum FM; Teo TH; Lee WW; Simarmata D; Harjanto S; Chua CL; Chan YF; Wee JK; Chow A; Lin RT; Leo YS; Le Grand R; Sam IC; Tong JC; Roques P; Wiesmüller KH; Rénia L; Rötzschke O; Ng LF
    EMBO Mol Med; 2012 Apr; 4(4):330-43. PubMed ID: 22389221
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Deciphering the protective role of adaptive immunity to CHIKV/IRES a novel candidate vaccine against Chikungunya in the A129 mouse model.
    Chu H; Das SC; Fuchs JF; Suresh M; Weaver SC; Stinchcomb DT; Partidos CD; Osorio JE
    Vaccine; 2013 Jul; 31(33):3353-60. PubMed ID: 23727003
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of Chikungunya virus immunity on Mayaro virus disease and epidemic potential.
    Webb EM; Azar SR; Haller SL; Langsjoen RM; Cuthbert CE; Ramjag AT; Luo H; Plante K; Wang T; Simmons G; Carrington CVF; Weaver SC; Rossi SL; Auguste AJ
    Sci Rep; 2019 Dec; 9(1):20399. PubMed ID: 31892710
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A small antigenic determinant of the Chikungunya virus E2 protein is sufficient to induce neutralizing antibodies which are partially protective in mice.
    Weber C; Büchner SM; Schnierle BS
    PLoS Negl Trop Dis; 2015 Apr; 9(4):e0003684. PubMed ID: 25905779
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anti-Chikungunya Virus Monoclonal Antibody That Inhibits Viral Fusion and Release.
    Tumkosit U; Siripanyaphinyo U; Takeda N; Tsuji M; Maeda Y; Ruchusatsawat K; Shioda T; Mizushima H; Chetanachan P; Wongjaroen P; Matsuura Y; Tatsumi M; Tanaka A
    J Virol; 2020 Sep; 94(19):. PubMed ID: 32699087
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A neutralizing monoclonal antibody targeting the acid-sensitive region in chikungunya virus E2 protects from disease.
    Selvarajah S; Sexton NR; Kahle KM; Fong RH; Mattia KA; Gardner J; Lu K; Liss NM; Salvador B; Tucker DF; Barnes T; Mabila M; Zhou X; Rossini G; Rucker JB; Sanders DA; Suhrbier A; Sambri V; Michault A; Muench MO; Doranz BJ; Simmons G
    PLoS Negl Trop Dis; 2013; 7(9):e2423. PubMed ID: 24069479
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chikungunya virus neutralization antigens and direct cell-to-cell transmission are revealed by human antibody-escape mutants.
    Lee CY; Kam YW; Fric J; Malleret B; Koh EG; Prakash C; Huang W; Lee WW; Lin C; Lin RT; Renia L; Wang CI; Ng LF; Warter L
    PLoS Pathog; 2011 Dec; 7(12):e1002390. PubMed ID: 22144891
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pathogenic Chikungunya Virus Evades B Cell Responses to Establish Persistence.
    Hawman DW; Fox JM; Ashbrook AW; May NA; Schroeder KMS; Torres RM; Crowe JE; Dermody TS; Diamond MS; Morrison TE
    Cell Rep; 2016 Aug; 16(5):1326-1338. PubMed ID: 27452455
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Near-germline human monoclonal antibodies neutralize and protect against multiple arthritogenic alphaviruses.
    Malonis RJ; Earnest JT; Kim AS; Angeliadis M; Holtsberg FW; Aman MJ; Jangra RK; Chandran K; Daily JP; Diamond MS; Kielian M; Lai JR
    Proc Natl Acad Sci U S A; 2021 Sep; 118(37):. PubMed ID: 34507983
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chikungunya virus host range E2 transmembrane deletion mutants induce protective immunity against challenge in C57BL/6J mice.
    Piper A; Ribeiro M; Smith KM; Briggs CM; Huitt E; Nanda K; Spears CJ; Quiles M; Cullen J; Thomas ME; Brown DT; Hernandez R
    J Virol; 2013 Jun; 87(12):6748-57. PubMed ID: 23552427
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development of a highly protective combination monoclonal antibody therapy against Chikungunya virus.
    Pal P; Dowd KA; Brien JD; Edeling MA; Gorlatov S; Johnson S; Lee I; Akahata W; Nabel GJ; Richter MK; Smit JM; Fremont DH; Pierson TC; Heise MT; Diamond MS
    PLoS Pathog; 2013; 9(4):e1003312. PubMed ID: 23637602
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A potent neutralizing IgM mAb targeting the N218 epitope on E2 protein protects against Chikungunya virus pathogenesis.
    Lam S; Nyo M; Phuektes P; Yew CW; Tan YJ; Chu JJ
    MAbs; 2015; 7(6):1178-94. PubMed ID: 26305993
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chikungunya-specific IgG and neutralizing antibody responses in natural infection of Chikungunya virus in children from India.
    Verma A; Nayak K; Chandele A; Singla M; Ratageri VH; Lodha R; Kabra SK; Murali-Krishna K; Ray P
    Arch Virol; 2021 Jul; 166(7):1913-1920. PubMed ID: 33907861
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Loss of TLR3 aggravates CHIKV replication and pathology due to an altered virus-specific neutralizing antibody response.
    Her Z; Teng TS; Tan JJ; Teo TH; Kam YW; Lum FM; Lee WW; Gabriel C; Melchiotti R; Andiappan AK; Lulla V; Lulla A; Win MK; Chow A; Biswas SK; Leo YS; Lecuit M; Merits A; Rénia L; Ng LF
    EMBO Mol Med; 2015 Jan; 7(1):24-41. PubMed ID: 25452586
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Liposomal Delivery of the RNA Genome of a Live-Attenuated Chikungunya Virus Vaccine Candidate Provides Local, but Not Systemic Protection After One Dose.
    Abeyratne E; Tharmarajah K; Freitas JR; Mostafavi H; Mahalingam S; Zaid A; Zaman M; Taylor A
    Front Immunol; 2020; 11():304. PubMed ID: 32194557
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Multiple immune factors are involved in controlling acute and chronic chikungunya virus infection.
    Poo YS; Rudd PA; Gardner J; Wilson JA; Larcher T; Colle MA; Le TT; Nakaya HI; Warrilow D; Allcock R; Bielefeldt-Ohmann H; Schroder WA; Khromykh AA; Lopez JA; Suhrbier A
    PLoS Negl Trop Dis; 2014 Dec; 8(12):e3354. PubMed ID: 25474568
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antibody-mediated enhancement aggravates chikungunya virus infection and disease severity.
    Lum FM; Couderc T; Chia BS; Ong RY; Her Z; Chow A; Leo YS; Kam YW; Rénia L; Lecuit M; Ng LFP
    Sci Rep; 2018 Jan; 8(1):1860. PubMed ID: 29382880
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chikungunya virus infection results in higher and persistent viral replication in aged rhesus macaques due to defects in anti-viral immunity.
    Messaoudi I; Vomaske J; Totonchy T; Kreklywich CN; Haberthur K; Springgay L; Brien JD; Diamond MS; Defilippis VR; Streblow DN
    PLoS Negl Trop Dis; 2013; 7(7):e2343. PubMed ID: 23936572
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fingolimod treatment abrogates chikungunya virus-induced arthralgia.
    Teo TH; Chan YH; Lee WW; Lum FM; Amrun SN; Her Z; Rajarethinam R; Merits A; Rötzschke O; Rénia L; Ng LF
    Sci Transl Med; 2017 Feb; 9(375):. PubMed ID: 28148838
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.